Table 2 Mean percentage (%) and standard deviation (SD) of CD4 + and CD8 + cells and their ratio before and after antileishmanial treatment at resting phase and following LSA or PMA/iono immunostimulation
CD4 + cells | CD8 + cells | CD4 + /CD8 + ratio | |||||||
|---|---|---|---|---|---|---|---|---|---|
Before treatment | After treatment | Controls | Before treatment | After treatment | Controls | Before treatment | After treatment | Controls | |
Resting phase | 30.28 (1.42) | 35.83 (1.61) | 41.74 (5.88) | 26.64 (2.13) | 18.59 (1.38) | 16.39 (2.90) | 1.14 (0.13) | 1.91 (0.07) | 2.58 (0.42) |
PMA/iono immunostimulation | 23.79 (8.49) | 30.59 (1.15) | 35.94 (5.50) | 18.09 (0.72) | 15.46 (0.55) | 11.99 (2.13) | 1.46 (0.06) | 1.97 (0.06) | 3.03 (0.39) |
LSA immunostimulation | 29.83 (0.60) | 35.49 (1.66) | 38.37 (5.51) | 26.50 (1.40) | 19.08 (0.88) | 16.43 (3.13) | 1.12 (0.04) | 1.86 (0.13) | 2.4 (0.52) |